Bioactivity | LUF6283 is a potent and orally active HCA(2) partial agonist, with a Ki of 0.55 µM. LUF6283 can achieve the beneficial lipid lowering effect of niacin without producing the unwanted cutaneous flushing side effect[1]. |
Target | EC50: 0.32 ± 0.06 μM (pERK1/2) |
In Vivo | LUF6283 (C57BL/6 mice, 400 mg/kg, Oral gavage, once a day for 4 weeks) has no effect on adipose tissue ATGL/HSL expression, and significantly reduces the expression of apolipoprotein B (APOB)[1]. |
Name | LUF6283 |
CAS | 92933-48-7 |
Formula | C8H12N2O2 |
Molar Mass | 168.19 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Li Z, et al. Effects of pyrazole partial agonists on HCA(2) -mediated flushing and VLDL-triglyceride levels in mice. Br J Pharmacol. 2012 Oct;167(4):818-25. |